关注
Douglas B Johnson
Douglas B Johnson
Associate Professor of Medicine, Vanderbilt University Medical Center
在 vumc.org 的电子邮件经过验证
标题
引用次数
引用次数
年份
Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma
W Hugo, JM Zaretsky, LU Sun, C Song, BH Moreno, S Hu-Lieskovan, ...
Cell 165 (1), 35-44, 2016
30372016
Fulminant myocarditis with combination immune checkpoint blockade
DB Johnson, JM Balko, ML Compton, S Chalkias, J Gorham, Y Xu, ...
New England Journal of Medicine 375 (18), 1749-1755, 2016
20282016
Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis
DY Wang, JE Salem, JV Cohen, S Chandra, C Menzer, F Ye, S Zhao, ...
JAMA oncology 4 (12), 1721-1728, 2018
20232018
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ...
The Lancet 395 (10241), 1907-1918, 2020
18502020
Completion dissection or observation for sentinel-node metastasis in melanoma
MB Faries, JF Thompson, AJ Cochran, RH Andtbacka, N Mozzillo, ...
New England Journal of Medicine 376 (23), 2211-2222, 2017
14002017
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy
H Shi, W Hugo, X Kong, A Hong, RC Koya, G Moriceau, T Chodon, R Guo, ...
Cancer discovery 4 (1), 80-93, 2014
10572014
Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data
F Finotello, C Mayer, C Plattner, G Laschober, D Rieder, H Hackl, ...
Genome medicine 11, 1-20, 2019
9402019
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study
JE Salem, A Manouchehri, M Moey, B Lebrun-Vignes, L Bastarache, ...
The Lancet Oncology 19 (12), 1579-1589, 2018
8832018
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
S Das, DB Johnson
Journal for immunotherapy of cancer 7 (1), 306, 2019
8112019
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
AM Menzies, DB Johnson, S Ramanujam, VG Atkinson, ANM Wong, ...
Annals of Oncology 28 (2), 368-376, 2017
8092017
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
JJ Moslehi, JE Salem, JA Sosman, B Lebrun-Vignes, DB Johnson
The Lancet 391 (10124), 933, 2018
7702018
Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology …
S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ...
Advances in anatomic pathology 24 (6), 311-335, 2017
6932017
Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders
DB Johnson, RJ Sullivan, PA Ott, MS Carlino, NI Khushalani, F Ye, ...
JAMA oncology 2 (2), 234-240, 2016
6282016
Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunooncology …
S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ...
Advances in anatomic pathology 24 (5), 235-251, 2017
6232017
Non-genomic and immune evolution of melanoma acquiring MAPKi resistance
W Hugo, H Shi, LU Sun, M Piva, C Song, X Kong, G Moriceau, A Hong, ...
Cell 162 (6), 1271-1285, 2015
6102015
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort …
JL McQuade, CR Daniel, KR Hess, C Mak, DY Wang, RR Rai, JJ Park, ...
The Lancet Oncology 19 (3), 310-322, 2018
5462018
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
DB Johnson, MV Estrada, R Salgado, V Sanchez, DB Doxie, SR Opalenik, ...
Nature communications 7 (1), 10582, 2016
5282016
Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: a systematic review and meta-analysis
S Lu, JE Stein, DL Rimm, DW Wang, JM Bell, DB Johnson, JA Sosman, ...
JAMA oncology 5 (8), 1195-1204, 2019
5232019
Immune-checkpoint inhibitors: long-term implications of toxicity
DB Johnson, CA Nebhan, JJ Moslehi, JM Balko
Nature Reviews Clinical Oncology 19 (4), 254-267, 2022
5092022
Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy
D Shae, KW Becker, P Christov, DS Yun, AKR Lytton-Jean, S Sevimli, ...
Nature nanotechnology 14 (3), 269-278, 2019
4802019
系统目前无法执行此操作,请稍后再试。
文章 1–20